Atherosclerosis and connective tissue disease;Athérosclérose et connectivites

Revue du Rhumatisme (Edition Francaise)

Volumn 68, Issue 10-11, 2001, Pages 931-943

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Atheroma; Ath rome; Inflammation; Lupus syst mique; Polyarthrite rhumato de; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; FIBRIN; GLUCOCORTICOID; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ADULT; AGE; AGED; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; MALE; MORTALITY; OBESITY; PATHOGENESIS; POSTMENOPAUSE; RHEUMATOID ARTHRITIS; RISK FACTOR; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0035726328     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(01)00210-1     Document Type: Short Survey

References (96)

1. Capron L. Évolution des théories sur l'athérosclérose. Rev Prat. 46:1996;533-537.
2. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus. 9:2000;170-175.
3. Urowitz M.B., Bookman A.A.M., Koehler B.E., Gordon D.A., Smuthe H.A., Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am J M. 60:1976;21-225.
4. Karsh, Klippel J., Balow J.E., Decker J.L. Mortality in lupus nephritis. Arthritis Rheum. 22:1979;764-769.
5. Wallace D.J., Podell T., Weiner J., Klinenberg J.R., Forouzesh S., et al. Systemic lupus erythematosus - survival patterns : experience with 609 patients. J Am Med Assoc. 245:1981;934-938.
6. Rosner S., Ginzler E.M., Diamond H.S., Weiner M., Schlesinger M., Fries J.F., et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum. 25:1982;612-617.
7. Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol. 14:1985;43-46.
8. Rubin L.A., Urowitz M.B., Gladman D.D. Mortality in systemic lupus erythematosus : the bimodal pattern revisited. Q J M. 55:1985;87-98.
9. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus : a prospective study of patients from a defined population. Medicine. 68:1989;141-150.
10. Shome G.P., Sakauchi M., Yamane K., Takemura H., Kashiwagi H. Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisone. Jpn J M. 28:1989;599-603.
11. Reveille J.S., Bartolucci A., Alarcon G.S. Prognosis in systemic lupus erythematosus : negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum. 33:1990;37-48.
12. Pistiner M., Wallace D.J., Nessim S., Metzger A.l, Klinenberg J.R. Lupus erythematosus in the 1980's : a survey of 570 patients. Semin Arthritis Rheum. 21:1991;55-64.
13. Petri M., Lakatta C., Magder L., Goldman D.W. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus : a longitudinal data analysis. Am J M. 96:1994;254-259.
14. Abu-Shakra M., Urowitz M.B., Gladman D.D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 22:1995;1259-1264.
15. Ward M.M., Pyun E., Studenski S. Causes of death in systemic lupus erythematosus. Arthritis Rheum. 38:1995;1492-1499.
16. Aranow C., Soliman N., Ginzler E.M. Changing patterns of mortality in systemic lupus erythematosus (SLE) over three decades at an urban center. abstract Arthritis Rheum. 39:(Suppl):1996;1118-1118.
17. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. Medicine. 78:1999;167-175.
18. Stahl-Hallengren C., Jonsen A., Nived O., Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden : increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol. 27:2000;685-691.
19. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy : a study of 36 necropsy patients. Am J M. 58:1975;243-264.
20. Haider Y.S., Roberts W.C. Coronary arterial disease in systemic lupus erythematosus : quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J M. 70:1981;761-775.
21. Gladman D.D., Urowitz M.B. Morbidity in systemic lupus erythematosus. J Rheumatol. 14:(Suppl 13):1987;223-226.
22. Bidani A.K., Roberts J.L., Schwartz M., Lewis E.J. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J M. 69:1980;849-858.
23. Godeau P., Guillevin L., Fecher J., Herreman G., Wechsler B. Manifestations cardiaques du lupus erythemateux aigu disseminé Nouv Presse M. 10:1981;2175-2178.
24. Petri M., Perez-Gutthann S., Spence D., Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J M. 93:1992;513-519.
25. Heart-Holmes M., Baethge B.A., Broadwell L., Wolf R.E. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol. 22:1995;450-454.
26. Rahman P., Urowitz M.B., Gladman D.D., Bruce I.N., Genest J. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 26:1999;2363-2368.
27. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42:1999;338-346.
28. Hospenpud J.D., Montanaro A., Hart M.V., Haines J.E., Specht H.D., Bennett R.M., et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J M. 77:1984;286-292.
29. Bruce I.N., Burns R.J., Gladman D.D., Urowitz M.B. SPECT dual isotope myocardial perfusion imaging in women with SLE. I. Prevalence and distribution of abnormalities. J Rheumatol. 27:2000;2372-2377.
30. Roman M.J., Salmon J., Sobel R., Sammaritano L., Devereux R.B., Locksin M.D. Premature atherosclerosis and myocardial hypertrophy in SLE and antiphospholipid antibody (APLA) syndrome. abstract Arthritis Rheum. 40:(Suppl):1997;302-302.
31. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42:1999;51-60.
32. Esdaile J.M., Abrahamowicz M., Grodzicky T., Senecal J.L., Panaritis T., Li Y., et al. Myocardial infarction (MI) and stroke in SLE : markdedly increased incidence after controlling for risk factors. abstract Arthritis Rheum. 41:(Suppl):1998;139-139.
33. Kvalvik A.G., Jones M.A., Symmons D.P.M. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed fromto1992. Scand J Rheumatol. 29:2000;29-37.
34. Monson R.R., Hall A.P. Mortality among arthritics. J Chron Dis. 29:1976;459-467.
35. Mutru O., Laakso M., Isomaki H., Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ. 290:1985;1797-1799.
36. Prior P., Symmons D.P.M., Scott D.L., Brown R., Hawkins C.F. Cause of death in rheumatoid arthritis. Br J Rheumatol. 23:1984;92-99.
37. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol. 11:1982;81-86.
38. Myllykangas-Luosujarvi R., Aho K., Kautiainen H., Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 22:1995;1065-1067.
39. Banks M., Flint J., Bacon P.A., Kitas G.D. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease. abstract Arthritis Rheum. 43:(Suppl):2000;385-385.
40. Del Rincon I., Wiliams K., Stern M.P., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. abstract Arthritis Rheum. 43:(Suppl):2000;385-385.
41. Kumeda Y., Inaba M., Kurioka Y., Goto H., Nagata M., Waki M., et al. Progression of atherosclerosis in common carotid artery (CCA) of patients with rheumatoid arthritis (RA). Thickening of intimamedia thickness (IMT) by ultrasonography. abstract Arthritis Rheum. 43:(Suppl):2000;385-385.
42. Formiga F., Meco J.F., Pinto X., Jacob J., Moga I., Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus. 10:2001;359-363.
43. Bruce I.N., Urowitz M.B., Gladman D.D., Hallett D.C. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 26:1999;2137-2143.
44. Jacobsson L.T., Turesson C., Hanson R.L., Pillemer S., Sievers M.L., Pettitt D.J., et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 44:2001;1170-1176.
45. Mcentegart A., Capell H.A., Creran D., Rumley A., Woodward M., Lowe G.D. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 40:2001;640-644.
46. Morgan S.L., Baggott J.E., Lee J.Y., Alarcon G.S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methothrexate therapy for rheumatoid arthritis : implications for cardiovascular disease prevention. J Rheumatol. 25:1998;441-446.
47. Tedgui A. Pathogénèse de l'athérosclérose. Encycl Méd Chir (éditions Scientifiques et Médicales Elsevier SAS, Paris), Neurologie, 17-046-A-20, 2001, 7 p.
48. Takahashi K., Takeya M., Sakashita N., Yoshimatsu M., Kinnouchi K. The role of macrophage scavenger receptors in atherogenesis. Shoenfield Y, Harats D, Wick G. Atherosclerosis and autoimmunity. 2001;29-40 Elsevier, Amsterdam.
49. Star Y.H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis : a report from the Committee on Vascular Lesions on the Council on Arteriosclerosis. American Heart Association. Circulation. 92:1995;1355-1374.
50. Ross R. Atherosclerosis. An inflammatory disease. N Engl J M. 340:1999;115-126.
51. Sirol M., Bouzamondo A., Sanchez P., Lechat P. Les satines préviennent-elles le risque d'accident vasculaire cérébral ? Ann Med Interne. 152:2001;188-193.
52. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J M. 344:2001;2016-2018.
53. Kwak B., Mulhaupt F., Mytt S., Mach F. Statins as a newly recognized type of immunomodulator. Nat M. 6:2000;1399-1402.
54. Petri M., Rubenoff R., Dallal G.E., Nadeau M.R., Selhub J., Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 348:1996;1120-1124.
55. Fijnheer R., Roest M., Haas F.J.L.M., De Groot P.G., Derksen R.H.W.M. Homocysteine, Methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus : a retrospective cohort study. J Rheumatol. 25:1998;1737-1742.
56. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11.
57. Xu Q., Willeit J., Marosi M., Kleindienst R., Oberhollenzer F., Kiechl S., et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclersosis. Lancet. 341:1993;255-259.
58. Beaudeux J.L., Jacob N., Giral P., Foglietti M.J., Bruckert E. Nouveaux marqueurs biologiques non lipidiques de l'athérosclérose. Ann Med Interne. 152:2001;169-179.
59. Cook P.J., Lip G.Y.H. Infectious agents and atherosclerotic vascular disease. Q J M. 89:1996;727-735.
60. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q. Is atherosclerosis an immunologically mediated disease ? Immunol Today. 16:1995;27-33.
61. Xu W., Dietrich H., Steiner H.G., Gown A.M., Schoel B., Mikuz G., et al. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 Arterioscler. Thromb. 12:1992;789-799.
62. George J., Shoenfeld Y., Afek A., Gilburd B., Keren P., Shaish A., et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol. 19:1999;505-510.
63. Lambert M., Boullier A., Hachulla E., Fruchart J.C., Teissier E., Hatron P.Y., et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus. 9:2000;299-300.
64. Phipps R.P. Atherosclerosis : the emerging role of inflammation and the CD40-CD40 ligand system. PNAS. 97:2000;6930-6932.
65. Liuzzo G., Kopecky S.L., Frye R.L., O'Fallon M., Maseri A., Goronzy J.J., et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 100:1999;2135-2139.
66. Gupta S., Pablo A.M., Jiang X.C., Wang N., Tall A.R., Schindler C. IFNγ potentiates atherosclerosis in apoE knock-out mice. J Clin Invest. 99:1997;2752-2761.
67. Schmidt D., Goronzy J.J., Weyand C.M. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 97:1996;2027-2037.
68. Pasceri V., Yeh E.T.H. A tale of two diseases atherosclerosis and rheumatoid arthritis. Circulation. 100:2000;2124-2126.
69. George J., Afek A., Gilburd B., Levy Y., Blank M., Kopolovic J., et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus. 6:1997;723-729.
70. George J., Afek A., Gilburd B., Blank M., Levy Y., Aron-Maor A., et al. Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta2-glycoprotein I. Circulation. 98:1998;1108-1115.
71. Matsuura E., Koike T. Accelerated atheroma and antiβ2 glycoprotein I antibodies. Lupus. 9:2000;210-216.
72. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of β2 glycoprotein I (apolipoprotein H) to human atheroscerotic plaques. Potential implications for lesion progression. Circulation. 99:1999;2227-2230.
73. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of β2 glycoprotein I and anticardiolipin antibodies inoxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 107:1997;569-573.
74. Meroni P.L., Raschi E., Camera M., Testoni C., Khamashta M.A., Tremoli E. Fluvastatin inhibits the activation of endothelial cells induced by antiphospholipid antibodies in vitro. abstract Arthritis Rheum. 43:(Suppl):2000;115-115.
75. Horkko S., Miller E., Dudl E., Reaen P., Curtiss L.K., Zvaifler N.J., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 98:1996;815-825.
76. Amangual O., Atsumi T., Khamashta M.A., Tinahones F., Hughes G.R. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol. 36:1997;964-968.
77. Cuadrado M.J., Tinahones F., Camps M.T., De Ramon E., Gomez-Zumaquero J.M., Mujic F., et al. Antiphospholipid, antibeta 2 glycoprotein I and anti-oxidized-low-density antibodies in antiphospholipid syndrome. Q J M. 91:1998;619-626.
78. Salonen J.T., Yla Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
79. Ryan M., Owens D., Kilbride B., Collins P., Johson A., Tomkin G.H. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction. Q J M. 91:1998;411-415.
80. Lopes Virella M.F., Virella G., Orchard T.J., Koskinen S., Evans R., Becker D.J., et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 90:1999;165-172.
81. Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern M. 154:1994;2605-2609.
82. Stemme S., Faver B., Holm J., Wiklund O., Witztum J., Hansson G. T lymphocytes from human atherosclerotic plaques recognise oxidised low density lipoprotein. Proc Natl Acad Sci USA. 92:1995;3893-3897.
83. Romero F.I., Amengual O., Atsumi T., Khamashta M.A., Tinahones F.J., Hughes G.R.V. Arterial disease in lupus and secondary antiphospholipid syndrome : association with anti-beta-2 glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol. 37:1998;883-888.
84. Hayem G., Nicaise Roland P., Palazzo E., De Bandt M., Tubach F., Weber M., et al. Anti-oxidized low-density lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus. 10:2001;346-351.
85. Palinski W., Miller E., Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malon-dialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 92:1995;821-825.
86. George J., Afek A., Gilburd B., Levy Y., Levkovitz H., Shaish A., et al. Hyperimmunization of ApoE deficient mice with homologous oxLDL suppresses early atherogenesis. Atherosclerosis. 138:1998;147-152.
87. Romero F., Atsumi T., Tinahones F.J., Gomez-Zumaquero J.M., Amengual O., Khamashta M.A., et al. Autoantibodies against malondialdehyde modified lipoprotein (a) in antiphospholipid syndrome. Arthritis Rheum. 42:1999;2606-2611.
88. Dinu A.R., Merril J.T., Shen C., Antonov I.V., Myones B.L., Lahita R.G. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 7:1998;355-360.
89. Abe H., Tsuboi N., Suzuki S., Sakuraba H., Takanashi H., Tahara J., et al. Anti-apolipoprotein A-I autoantibody : characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol. 28:2001;990-995.
90. Reiss A.B., Malhotra S., Javitt N.B., Grossi E.A., Galloway A.C., Montesinos M.C., et al. Occupancy of C1q receptors on endothelial cells (EC) by immune complexes downregulates mRNA for sterol 27-hydroxylase (27-OH'ase), the major mediator of extra-hepatic cholesterol metabolism. abstract Arthritis Rheum. 41:1998;79-79.
91. Kabakov A.E., Tertov V.V., Saenko V.A., Poverenny A.M., Orekhov A.N. The atherogenic effect of lupus sera : systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 63:1992;214-220.
92. Bruce I.N., Gladman D.D., Urowitz M.B. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus : a quality improvement study. Clin Exp Rheumatol. 16:1998;435-440.
93. Petri M. Hydroxychloroquine used in Baltimore Lupus Cohort : effects on lipids, glucose and thrombosis. Lupus. 5:(Suppl 1):1996;16-22.
94. Krempf M. Recommandations diététiques aux dyslipidémiques. Ann Med Interne. 152:2001;198-200.
95. Munford R.S. Statins and the acute phase response. N Engl J M. 344:2001;2016-2018.
96. Ilowite N.T. Premature atherosclerosis in systemic lupus erythematosus. J Rheumatol. 27:(Suppl 58):2000;15-19.